ERBB2 and urinary bladder carcinoma: Due to its favorable properties, phase I dose-escalation studies were conducted in patients with HER2-positive cancers, including bladder cancer, either as a monotherapy (NCT03330561) or in combination with Atezolizumab (NCT03650348).